[1] |
ZHANG Qi, CHEN Min, ZHANG Shiqing.
Conditional approval of medical devices in the United States and enlightenment
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1007-1010.
|
[2] |
.
Annual report of national adverse drug reaction monitoring (2022)
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 712-719.
|
[3] |
ZHAO Yan, LIU Wenbo, ZHAO Yifei, LI Dong, ZHENG Lijia, SONG Yana, ZHAO Yujuan, DONG Fang.
Applicability of patient registry research to regulation of medical devices
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 423-427.
|
[4] |
ZHAO Yan, LI Dong, CHENG Yinjie, JIANG Bin, ZHAO Yifei, DONG Fang, YUAN Jing.
Advances in studies on post-market safety data sources and signal detection for medical devices
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 236-240.
|
[5] |
ZHAO Yan, LI Yao, SONG Ya’na, ZHENG Lijia, LI Dong, ZHAO Yifei, BIAN Rongrong, DONG Fang.
Post-marketing active monitoring of medical devices under vigilance
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1385-1390.
|
[6] |
ZHENG Yi, ZHAI Yinghong, GUO Xiaojing, XU Jinfang, CHI Lijie, GUO Zhijian, CHEN Chenxin, LIANG Jizhou, WEI Lianhui, CHEN Xiao, YE Xiaofei, HE Jia.
Thyroid immune-related adverse reactions of immune checkpoint inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 92-95.
|
[7] |
SHEN Chuanyong, SONG Yana, ZHAO Yan, ZHENG Lijia, ZHAO Yifei, LI Dong.
Thoughts on constructing vigilance system of Chinese medical device in the new era
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 697-701.
|
[8] |
TENG Yingying, LI Chaiquan, XU Yang, TANG Xun, GAO Pei.
Progress in the application of real-world data in post-market surveillance of medical devices
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 233-238.
|
[9] |
LIANG Jiaqi, SHAO Rong, LIU Pengcheng, LI Ming, RENG Jingtian, TANG Ren, WANG Yue.
Characteristics of dear health care provider letters in Europe and America
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 275-278.
|
[10] |
CUI Huanhuan, PEI Xiaojing, LI Yanrong, LIU Wendong, WANG Haixue, LAN Gongtao, WANG Tao.
The practice and consideration of pharmacovigilance during clinical trials in China
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1050-1054.
|
[11] |
ZHAO Yifei, ZHAO Yan, DONG Fang, ZHENG Lijia, LI Dong, SONG Yana.
Introduction and inspiration of international medical device regulators forum patient registry guidelines
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1091-1096.
|
[12] |
BAI Hehe, NIE Xiaojing, XIA Li, MA Li, WANG Jinping, PENG Lirong.
Effect evaluation of adverse drug reactions monitoring based on the Chinese hospital pharmacovigilance system
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1136-1139.
|
[13] |
TAN Jing, LIU Chunrong, HUANG Shiyao, GAO Pei, WANG Yang, LI Chen, HE Yong, YUAN Hong, WANG Wen, LI Ling, XIONG Yiquan, REN Yan, YAO Minghong, ZHAO Yan, DONG Fang, SHEN Chuanyong, SUN Xin.
Expert consensus on post-marketing risk monitoring technology for high-risk implantable passive medical devices based on real world data
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 13-17.
|
[14] |
ZHENG Chao, WU Yan, ZHANG Lan, HU Kai, ZENG Ye, WANG Wen, WANG Ling.
Methods for risk trend analysis of EU post-marketing surveillance for medical devices
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 79-82.
|
[15] |
MAO Zhenbin, LIU Shuyu.
Implications of Regulatory Science for the Construction of Medical Device Vigilance Systems
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 601-605.
|